|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Supplementary Table 4. Details of three patients with HBsAg loss** | | | | | | | |
| **Patient ID** | **Serum HBsAg (IU/mL)** | **HBsAb (IU/mL)** | **cccDNA (copies/cell)** | **Serum pgRNA (copies/mL)** | **Integrated events** | **Liver pathology** | **Therapeutic regimen** | |
|
|
| F807 | < 0.05 | 73.93 | Undetected | Undetected | 0 | G2S1-2 | Entecavir for 22 months | |
| F808 | < 0.05 | 11.8 | 0.1 | Undetected | 0 | G1S1 | Patient treated with 38 months of entecavir and regiment change to pegylated interferon–entecavir combination therapy for 12 weeks followed by pegylated interferon for 36 weeks (HBsAg loss appearing after 12 weeks of pegylated interferon treatment alone) | |
| R228 | < 0.05 | 9.46 | 0.03 | Undetected | 3 | G1S1 | Patient treated with 13 months of TDF and regimen change to TDF-pegylated interferon combination therapy for 72 weeks (HBsAg loss appearing after 44 weeks of combination therapy) | |

cccDNA, covalently closed circular DNA; HBsAb, hepatitis B surface antibody; HBsAg, hepatitis B surface antigen; pgRNA, pre-genomic RNA; SD, standard deviation; TDF, tenofovir disoproxil fumarate.